#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Neonatal alloimmune thrombocytopenia ROHHAD syndrome Rhabdoid tumour Microvillous inclusion disease Inflammatory myofibroblastic tumour Hyperchylomicronaemia Mantle cell lymphoma Non-Hodgkin's lymphoma unspecified histology indolent Follicular lymphoma stage I Keratosis follicular Thrombotic thrombocytopenic purpura Systemic sclerosis pulmonary Brain injury Bronchiolitis Glomerulonephritis minimal lesion More trials…

    Learn about Rare Diseases

    Gaucher’s disease type III – Treatment Breast angiosarcoma – Life with Disease IgA nephropathy – Life with Disease Mast cell activation syndrome – Trials in Disease Haemolytic uraemic syndrome Congenital nephrogenic diabetes insipidus – Treatment Myxofibrosarcoma – Life with Disease Glycogen storage disease type V – Life with Disease Propionic acidaemia – Basic Information Gaucher’s disease type I – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Golcadomide Clindamycin Phosphate Linezolid Naxitamab Ribonucleic Acid Izaflortaucipir (18F) D5-Ethyl-Beta-D-Glucuronide Batoprotafib INDAPAMIDE HEMIHYDRATE Eribulin Mesylate Cenerimod Vosoritide Tacrolimus Monohydrate N-Tec Ravulizumab Metolazone Risedronate Sodium PETHIDINE HYDROCHLORIDE Secukinumab Levofloxacin More therapies…

    Learn about Your Condition

    Renal cancer Osteochondrodysplasia Reperfusion injury Skin papilloma Aortic disorder Tympanic membrane perforation Hepatobiliary disease Ovarian cancer stage III Migraine without aura Fibrous dysplasia of bone Nicotine dependence Juvenile psoriatic arthritis Plasma cell myeloma refractory Glucose tolerance impaired Petit mal epilepsy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Noe LGA Gesundheit Region Mitte GmbH

Noe LGA Gesundheit Region Mitte GmbH

Dunant-Platz 1, St. Poelten, 3100, Austria

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke

    Not recruiting

    3 1
    Investigated Drugs:
    • Asundexian
    Austria Belgium Bulgaria Czechia Denmark Finland +14

  • Study of Upadacitinib for Adolescents and Adults with Moderate to Severe Eczema

    Not recruiting

    3 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Upadacitinib
    Austria Belgium Bulgaria Croatia Czechia Denmark +9

  • Study Comparing MK-7684A (Vibostolimab and Pembrolizumab) with Pembrolizumab for Adults and Children with High-Risk Stage II-IV Melanoma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Pembrolizumab
    • Vibostolimab
    Austria Belgium France Germany Ireland Italy +3

  • Study Comparing Zanubrutinib, Obinutuzumab, and Rituximab with Lenalidomide and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Lenalidomide
    • Obinutuzumab
    • Rituximab
    Austria Belgium Bulgaria Czechia France Germany +8

  • Study Comparing Axicabtagene Ciloleucel and Standard Treatment for Adults with High-Risk Large B-Cell Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma
    Investigated Drugs:
    • Axicabtagene Ciloleucel
    • Cyclophosphamide
    • Dexamethasone
    Austria France Germany Italy The Netherlands Portugal +1

  • Study of Isatuximab with Lenalidomide and Dexamethasone for Elderly Patients (70+) with Newly Diagnosed Multiple Myeloma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Isatuximab
    Austria Greece

  • Study on the Safety and Effectiveness of Vibrio Alginolyticus Collagenase for Patients with Dupuytren’s Contracture

    Not recruiting

    1 1
    Investigated Diseases:
    • Dupuytren’s contracture
    Investigated Drugs:
    • Vibrio Alginolyticus Collagenase
    Austria Germany Italy Sweden

  • Study on Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Carfilzomib
    • Dexamethasone
    • Dexamethasone Dihydrogen Phosphate Disodium Ph. Eur.
    Austria Germany

  • Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Apixaban
    • Asundexian
    Austria Belgium Bulgaria Czechia Denmark Estonia +16

  • Study on Tafasitamab and Lenalidomide with Standard Therapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma Patients

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma
    Investigated Drugs:
    • Betamethasone Sodium Phosphate
    • Cyclophosphamide
    • Doxorubicin Hydrochloride
    Austria Czechia France Germany Hungary Ireland +5
Previous Page
1 … 7 8 9

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!